Regeneron chief scientific officer and Regeneron Laboratories president George Yancopoulos said the approval of Eylea in Japan presents new treatment option for wet AMD patients and physicians.
"We are pleased to offer this new therapeutic option, which we hope will decrease the challenges of treatment for wet-AMD patients in Japan," Yancopoulos added.
The MHLW approval of Eylea is based upon the results of two phase 3 clinical studies, according to the company.
Eylea was approved for wet AMD in the US in November 2011 and in Australia earlier this year.
Eylea is a recombinant fusion protein having portions of human VEGF receptors 1 and 2 extracellular domains fused to the Fc portion of human IgG1 and formulated as an iso-osmotic solution for intravitreal administration.